Skip to main content
. Author manuscript; available in PMC: 2024 May 1.
Published in final edited form as: Adv Ther (Weinh). 2023 Feb 16;6(5):2200219. doi: 10.1002/adtp.202200219

Figure 3. In vivo efficacy of intramuscular SAM delivery using luciferase SAM with expression assessed 10 days following injection.

Figure 3.

(A) Selection of polymer to SAM w/w ratio and (B) Particle mass fraction of DMG-PEG2k using nanoparticle 7–90,c12–63, 50% Sc12. (C) Violin plots of intramuscular luminescence measured at day 10 for nine PBAE NPs compared to naked SAM for a dose of 200 ng injected in 20 μL injection volume. N = 10 IM injections per polymer; assessed using one-way ANOVA corrected for multiple comparisons to naked SAM injection. (D) Structures of lead polymers for intramuscular administration. (E) Representative IVIS images with the top two nanoparticle formulations compared to naked SAM. (F) Relationship between in vitro transfection of C2C12 cells in 96-well plates at a dose of 5 ng/well and in vivo luminescence following intramuscular administration.